These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 3302349

  • 1. [Immunotherapy of terminal-stage malignant tumors with the immunopotentiator OK-432--a comparison between SU-PS test-responder and -nonresponder patients].
    Yagi Y, Yagi S, Ichiki H.
    Gan No Rinsho; 1987 Jun; 33(7):815-21. PubMed ID: 3302349
    [Abstract] [Full Text] [Related]

  • 2. Immunotherapy of patients with terminal-stage malignant tumors with an immunopotentiator OK-432--a comparison of SU-PS test-responding and -nonresponding patients.
    Yagi Y, Yagi S.
    Int J Immunopharmacol; 1988 Jun; 10(4):451-61. PubMed ID: 3049405
    [Abstract] [Full Text] [Related]

  • 3. [Role of immune skin reactions in progressive lung cancer during the administration of OK-432--relation to reactions to DNCB, PPD and Su-PS].
    Katada H, Nishikawa K, Yoneda T, Kitamura H, Nakajima A, Mikami R.
    Gan To Kagaku Ryoho; 1987 Jan; 14(1):61-70. PubMed ID: 3026256
    [Abstract] [Full Text] [Related]

  • 4. [Clinical significance of Su-polysaccharide (Su-PS) skin test in patients with primary lung cancer treated with chemotherapy and administration of OK-432, with special reference to the therapeutic effect and prognosis].
    Horiuchi M, Sato K, Nakarai I, Shinoda A.
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):468-74. PubMed ID: 2181937
    [Abstract] [Full Text] [Related]

  • 5. [Clinical significance of a skin test (SU-PS) for immune responses in patients with gastrointestinal cancer treated with OK-432].
    Miyamoto Y, Takeshita M, Izuo M.
    Gan To Kagaku Ryoho; 1986 Oct; 13(11):3229-35. PubMed ID: 3777960
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Relation between prognosis and the Su-PS skin reaction in patients with non-resected primary lung cancer receiving OK-432].
    Nakarai I, Rikitake H, Koga T, Hayashi A, Harada Y, Takamoto M, Ishibashi T, Shinoda A, Sagawa K.
    Gan To Kagaku Ryoho; 1987 Nov; 14(11):3050-7. PubMed ID: 2823723
    [Abstract] [Full Text] [Related]

  • 9. [Evaluation of immune status in gastric cancer using Su-Ps skin test].
    Ogawa T, Yakawa H, Ogawa K, Otani Y, Kawata H, Haga S, Kasihara T, Sakakibara N.
    Gan To Kagaku Ryoho; 1984 Oct; 11(10):2221-6. PubMed ID: 6385863
    [Abstract] [Full Text] [Related]

  • 10. [Effect of immunotherapy using the non-specific immunopotentiator OK-432 in malignant ovarian tumors--selecting appropriate cases for immunotherapy].
    Nishida Y, Sakakibara K, Kano T, Ohta M, Tomoda Y.
    Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jul; 38(7):1017-25. PubMed ID: 3746020
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of streptococcal lyzate OK-432 on peripheral blood mononuclear cells in gastric cancer patients.
    Nakayama F, Iwagaki H, Gouchi A, Hizuta A, Isozaki H, Takakura N, Tanaka N.
    J Med; 1998 Jul; 29(3-4):199-215. PubMed ID: 9865458
    [Abstract] [Full Text] [Related]

  • 18. [Clinical studies on the reaction of the skin to various doses of Su-polysaccharide in cancer patients].
    Sato M, Sakai K, Kimura S, Tamaki Y, Kiyasu Y, Joko Y, Ogoshi T.
    Gan To Kagaku Ryoho; 1985 Feb; 12(2):245-9. PubMed ID: 3970550
    [Abstract] [Full Text] [Related]

  • 19. Immunological differences between squamous cell cancer patients treated with and without biological response modifier (OK-432): evaluation at a period of more than one year after the last treatment.
    Yoshimura Y, Oka M, Harada T, Inou Y, Saito H, Odagawa T, Matsumoto K.
    J Osaka Univ Dent Sch; 1989 Dec; 29():117-22. PubMed ID: 2577382
    [Abstract] [Full Text] [Related]

  • 20. [Local immunotherapy with streptococcal preparation, OK-432 in superficial bladder tumors, and common antigens between OK-432 and the tumor].
    Fujioka T, Shiraishi M, Tanji S, Koike H, Suzuki K, Kumagai K, Aoki H, Sakuma Y, Ohhori T, Kubo T.
    Hinyokika Kiyo; 1989 Feb; 35(2):253-7. PubMed ID: 2735236
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.